UTHR United Therapeutics (UTHR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001082554
C-suite buying · 1Congress · 1Form 144 · 10
Funds added, last quarter
428
13F, latest reported quarter
Conversions, 180 days
165
Codes C/M, not in net · $190.6M priced
What the filings say about UTHR
Insiders, 180 days
-$768.2M net sold
1 buyer · 5 sellers · 37% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2025-10-31
Planned sales (Form 144), 90 days
$344.4M
10 notices
United Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, UNITED THERAPEUTICS Corp insiders sold a net $768.2M of stock across 5,264 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 3630 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3629 sales), the last on Oct 22, 2026.
- The trade is 0.1% of the 333,743 shares held after it.
- 1 other insider sold within 30 days.
- 428 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairperson & CEO ROTHBLATT MARTINE A sold about $115.5K of UTHR under a 10b5-1 plan on Oct 23, 2026; 1 other insider sold within 30 days and 428 funds added in the latest 13F quarter.Context
- 3630 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3629 sales), the last on Oct 22, 2026.
- The trade is 0.2% of the 333,043 shares held after it.
- 1 other insider sold within 30 days.
- 428 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairperson & CEO ROTHBLATT MARTINE A sold about $405.2K of UTHR under a 10b5-1 plan on Oct 23, 2026; 1 other insider sold within 30 days and 428 funds added in the latest 13F quarter.Context
- 3630 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3629 sales), the last on Oct 22, 2026.
- The trade is 0.3% of the 332,005 shares held after it.
- 1 other insider sold within 30 days.
- 428 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairperson & CEO ROTHBLATT MARTINE A sold about $601.8K of UTHR under a 10b5-1 plan on Oct 23, 2026; 1 other insider sold within 30 days and 428 funds added in the latest 13F quarter.Context
- 3630 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3629 sales), the last on Oct 22, 2026.
- The trade is 0.3% of the 330,988 shares held after it.
- 1 other insider sold within 30 days.
- 428 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairperson & CEO ROTHBLATT MARTINE A sold about $590.7K of UTHR under a 10b5-1 plan on Oct 23, 2026; 1 other insider sold within 30 days and 428 funds added in the latest 13F quarter.Context
- 3630 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3629 sales), the last on Oct 22, 2026.
- The trade is 0.5% of the 329,338 shares held after it.
- 1 other insider sold within 30 days.
- 428 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairperson & CEO ROTHBLATT MARTINE A sold about $960.0K of UTHR under a 10b5-1 plan on Oct 23, 2026; 1 other insider sold within 30 days and 428 funds added in the latest 13F quarter.5,264 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$768.2M over 180 days
-$332.1M over 90 days
the lowest in Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
428 funds bought in last quarter
more than 97% of Pharma & Biotech
Revenue
+10.6% year over year
more than 60% of Pharma & Biotech
Margin
41.9% net margin
more than 94% of Pharma & Biotech
Buybacks
$1.5B repurchased, FY to 2026-06-30
more than 96% of Pharma & Biotech
Short interest
9.2% of the float short (float per yahoo 2026-10-26) · 3.6 days to cover · settled 2026-09-30
more than 65% of Pharma & Biotech
What changed in the last 30 days
Oct 26Chairperson & CEO ROTHBLATT MARTINE A sold $107.7M under a 10b5-1 plan (324 trades, Sep 25 to Oct 23)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 16EVP & GENERAL COUNSEL MAHON PAUL A sold $9.2M under a 10b5-1 plan (16 trades, Oct 1 to Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 15Officer PAUL MAHON filed to sell $4.5M by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Director MARTINE ROTHBLATT filed to sell $113.3M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Officer PAUL MAHON filed to sell $4.7M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch UTHR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+40.6%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns UTHR: institutional holders (13F)
13F holdings, latest reported quarter
5,294,529 sh
$2.9B
2,777,777 sh
$1.5B
1,919,429 sh
$1.0B
1,918,256 sh
$1.0B
1,898,064 sh
$1.0B
Congress trades in UTHR
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Bought 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-06-11 · disclosed 63 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
UTHR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
PAUL MAHON
Filed 2026-10-15
$4.5M
PAUL MAHON
Filed 2026-10-01
$4.7M
MARTINE ROTHBLATT
Filed 2026-10-01
$113.3M
PAUL MAHON
Filed 2026-09-17
$4.1M
NILDA MESA
Filed 2026-09-14
$115.3K
UTHR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Health Care ETF
$24.6M position · as of 2026-06-30
6.9%
Saratoga Health & Biotechnology Fund
$645.9K position · as of 2026-05-31
6.2%
LIVE OAK HEALTH SCIENCES FUND
$2.9M position · as of 2026-07-31
5.1%
Poplar Forest Partners Fund
$18.6M position · as of 2026-06-30
4.9%
F/m Emerald Life Sciences Innovation ETF
$4.4M position · as of 2026-05-31
4.2%
Invesco Biotechnology & Genome ETF
$11.5M position · as of 2026-07-31
4.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
30 registered trials, 8 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
5
Phase 2
0 active
12
Phase 3
3 active
5
Phase 4
1 active
4
Not applicable
2 active
3
Multi-phase
2 active
What changed recently
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With E
2026-09-10 · Completion moved 2029-03 → 2029-11
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Martine Rothblatt
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$18.0M
$149.9M
$9.4M
+221%
+101%
2024
$23.0M
$120.3M
$10.0M
+132%
+56%
2023
$17.0M
-$10.8M
$7.0M
+45%
+44%
2022
$5.3M
$41.2M
$2.4M
+83%
+39%
2021
$3.5M
$50.4M
$2.0M
+42%
+24%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $768.2M sold by insiders over 180 days, 428 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $344.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
UTHR financials
Revenue growth
+10.6%
XBRL, annual
Net margin
41.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.2B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM UTHR
| FY Dec 2025 | $3.2B |
| FY Dec 2024 | $2.9B |
| FY Dec 2023 | $2.3B |
| FY Dec 2022 | $1.9B |
| FY Dec 2021 | $1.7B |
| Jun 2026 | $783.3M |
| Mar 2026 | $781.5M |
| Dec 2025 | $790.2M |
| Sep 2025 | $799.5M |
| Jun 2025 | $798.6M |
| Mar 2025 | $794.4M |
| Dec 2024 | $735.9M |
| Sep 2024 | $748.9M |
At each fiscal year end
Single quarter
Net margin, TTM
+41.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM UTHR
| FY Dec 2025 | +41.9% |
| FY Dec 2024 | +41.5% |
| FY Dec 2023 | +42.3% |
| FY Dec 2022 | +37.6% |
| FY Dec 2021 | +28.2% |
| Jun 2026 | +42.5% |
| Mar 2026 | +35.2% |
| Dec 2025 | +46.1% |
| Sep 2025 | +42.4% |
| Jun 2025 | +38.8% |
| Mar 2025 | +40.6% |
| Dec 2024 | +40.9% |
| Sep 2024 | +41.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.1B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM UTHR
| FY Dec 2025 | $1.0B |
| FY Dec 2024 | $1.1B |
| FY Dec 2023 | $747.6M |
| FY Dec 2022 | $663.7M |
| FY Dec 2021 | $477.4M |
| Jun 2026 | $205.6M |
| Mar 2026 | $362.5M |
| Dec 2025 | $173.3M |
| Sep 2025 | $351.6M |
| Jun 2025 | $129.5M |
| Mar 2025 | $386.3M |
| Dec 2024 | $254.5M |
| Sep 2024 | $300.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity UTHR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt UTHR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+19.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity UTHR
| FY Dec 2025 | +19.7% |
| FY Dec 2024 | +19.2% |
| FY Dec 2023 | +18.3% |
| FY Dec 2022 | +16.6% |
| FY Dec 2021 | +12.9% |
| Jun 2026 | +19.3% |
| Mar 2026 | +20.3% |
| Dec 2025 | +19.7% |
| Sep 2025 | +20.0% |
| Jun 2025 | +19.3% |
| Mar 2025 | +19.9% |
| Dec 2024 | +19.2% |
| Sep 2024 | +18.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+17.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets UTHR
| FY Dec 2025 | +17.5% |
| FY Dec 2024 | +16.4% |
| FY Dec 2023 | +14.9% |
| FY Dec 2022 | +13.0% |
| FY Dec 2021 | +9.7% |
| Jun 2026 | +17.3% |
| Mar 2026 | +17.8% |
| Dec 2025 | +17.5% |
| Sep 2025 | +17.6% |
| Jun 2025 | +17.0% |
| Mar 2025 | +17.0% |
| Dec 2024 | +16.4% |
| Sep 2024 | +15.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
Return on invested capital UTHR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+20.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed UTHR
| FY Dec 2025 | +21.4% |
| FY Dec 2024 | +21.2% |
| FY Dec 2023 | +19.6% |
| FY Dec 2022 | +18.5% |
| FY Dec 2021 | +12.1% |
| Jun 2026 | +20.0% |
| Mar 2026 | +21.9% |
| Dec 2025 | +21.4% |
| Sep 2025 | +22.9% |
| Jun 2025 | +21.8% |
| Mar 2025 | +22.2% |
| Dec 2024 | +21.2% |
| Sep 2024 | +20.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
21.22x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing UTHR
| FY Dec 2025 | 17.47x |
| FY Dec 2024 | 14.33x |
| FY Dec 2023 | 11.10x |
| FY Dec 2022 | 18.54x |
| FY Dec 2021 | 21.56x |
| Jun 2026 | 19.39x |
| Mar 2026 | 21.90x |
| Dec 2025 | 17.47x |
| Sep 2025 | 15.87x |
| Jun 2025 | 11.21x |
| Mar 2025 | 12.29x |
| Dec 2024 | 14.33x |
| Sep 2024 | 15.76x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value UTHR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield UTHR
| FY Dec 2025 | +5.0% |
| FY Dec 2024 | +6.9% |
| FY Dec 2023 | +7.2% |
| FY Dec 2022 | +5.2% |
| FY Dec 2021 | +4.9% |
| Jun 2026 | +4.8% |
| Mar 2026 | +3.9% |
| Dec 2025 | +5.0% |
| Sep 2025 | +5.9% |
| Jun 2025 | +8.3% |
| Mar 2025 | +8.2% |
| Dec 2024 | +6.9% |
| Sep 2024 | +5.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
2.37x
P/E over trailing EPS growth of 9%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing UTHR
| FY Dec 2025 | 1.32x |
| FY Dec 2024 | 0.59x |
| FY Dec 2023 | 0.35x |
| FY Dec 2022 | 0.37x |
| FY Dec 2021 | n/a |
| Jun 2026 | 2.16x |
| Mar 2026 | 2.75x |
| Dec 2025 | 1.32x |
| Sep 2025 | 0.98x |
| Jun 2025 | 0.62x |
| Mar 2025 | 0.66x |
| Dec 2024 | 0.59x |
| Sep 2024 | 0.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.3B | $1.9B |
| Gross profit | $2.8B | $2.6B | $2.1B | $1.8B |
| Operating income | $1.5B | $1.4B | $1.2B | $979.7M |
| Net income | $1.3B | $1.2B | $984.8M | $727.3M |
| EPS (diluted) | 27.86 | 24.64 | 19.81 | 15.00 |
| Operating cash flow | $1.6B | $1.3B | $978.0M | $802.5M |
| Cash | $1.6B | $1.7B | $1.2B | $961.2M |
| Buybacks | $1.0B | $1.0B | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
UTHR Stock Sonar score 5/7 axes
Find similar shapesCompareUTHR ranks highest on profitability (91st percentile) and growth (60th), and lowest on insider conviction (28th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
UTHR filings, in plain words
Are United Therapeutics insiders buying or selling UTHR?
In the 180 days to 2026-10-27, United Therapeutics insiders were net sellers, a net $768.2M: $863.9K of purchases and $769.1M of sales reported on Form 4, by 1 buyer and 5 sellers.
Have members of Congress traded UTHR?
Yes. In the year to 2026-10-27, 1 House member disclosed buying UTHR and 1 House member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31.
Are there planned insider sales of UTHR?
Yes. 10 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $344.4M of stock; the latest, by PAUL MAHON, was filed 2026-10-15.
Read the full summary
In the 180 days to 2026-10-27, United Therapeutics insiders were net sellers of UTHR, a net $768.2M across purchases and sales reported on Form 4 by 1 buyer and 5 sellers. Sales outweighed purchases more than tenfold by value. 37% of the 1683 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying UTHR and 1 member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31. Insiders filed 10 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $344.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
